A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. [electronic resource]
Producer: 20150703Description: 2230-2236 p. digitalISSN:- 1569-8041
- 3' Untranslated Regions -- genetics
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
- Carcinoma, Squamous Cell -- drug therapy
- Cetuximab
- Cisplatin -- administration & dosage
- Cyclin-Dependent Kinase Inhibitor p16 -- biosynthesis
- Disease-Free Survival
- Drug Resistance, Neoplasm -- genetics
- Female
- Gene Expression Regulation, Neoplastic
- Genotype
- Head and Neck Neoplasms -- drug therapy
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- drug therapy
- Prognosis
- Proto-Oncogene Proteins -- biosynthesis
- Proto-Oncogene Proteins p21(ras)
- Squamous Cell Carcinoma of Head and Neck
- ras Proteins -- biosynthesis
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.